Charterhouse invests in Phastar

The firm is currently investing from its 10th-generation fund, which closed on €2.3bn in November 2016. Investments are typically within the €300m-4bn size bracket.

A source close to the situation told Unquote: "Charterhouse has been closely following the company, developing strong conviction in the opportunity for Phastar and building a strong relationship with management."

The company's founder, Kevin Kane, is reinvesting alongside the firm and will remain CEO, as well as retain a significant stake in the business alongside the existing management team.

As part of the transaction, Nick Edwards will become non-executive chair of the company. Edwards is currently chair of Prescient Healthcare Group, was co-founder of Kinapse life sciences consultancy, and previously served as lead partner in Accenture's Pharmaceutical R&D Practice.

Charterhouse declined to comment.

Company
Founded in 2007, Phastar is a biometrics clinical research organisation offering statistical consulting, clinical trial reporting, data science and data management services. Headquartered in London and North Carolina, the business operates across an international network of 12 offices and employs 250 people.

People
Charterhouse Capital Partners – James Cocker (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• UK / Ireland
• Support services
• United Kingdom
• Charterhouse Capital Partners